Tenax Therapeutics, Inc. (TENX)
TENXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.76
+0.0707 (+4.18%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $81.05m
- P/E
- –
- EPS, last 4 quarters
- $-1.39
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.31 to $19.40
- Average volume
- 3.19m
- Previous close
- $1.69
Analysts
10 coveringBuy6 buy, 4 hold, 0 sell
Targets a year out average $9.63, +446.9% from here
Earnings
next estimate $-0.3400Next report
Dec 2025
+69.8%
Mar 2026
+12.5%
Jun 2026
+7.9%
Sep 2026
+11.4%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$16.81m | -$16.45m | -$16.57m | -$18.78m |
| Net income | -$15.80m | -$15.54m | -$15.72m | -$17.80m |
News
8 latest- Tenax Therapeutics (TENX) Upgraded to Buy: Here's WhyZacks · 10 hours ago
- Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateFintel · 4 days ago
- Monday 9/21 Insider Buying Report: TH, TENXBNK Invest · Sep 21, 2026
- Tenax's Phase 3 Study For TNX-103 Fails To Meet Primary Endpoint; Shows Success In Other Measures RTTNews · Aug 30, 2026
- Biotech Gainers: TENX Rebound, KURA Momentum, AVXL Profit, RNXT Data Drive Gains RTTNews · Aug 25, 2026
- 5 After-Hours Healthcare Gainers: AMIX, PMI, TENX, KURA, NEPH RTTNews · Aug 24, 2026
- Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan CaseMarketBeat · Aug 11, 2026
- Tenax Posts Wider Q2 Loss; Phase 3 Heart Drug Results Due In August RTTNews · Jul 31, 2026
The company
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- tenaxthera.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.